EFFICIENCY ANALYSIS OF ALLOKINALFA IN THE COMPLEX TREATMENT OF RECURRENT HERPES ZOSTER

Abstract

The aim of the work – to study the therapeutic efficiency of new immunotropic Allokin-alpha drug, the operating substance of which is a cytokine-like peptide of alloferon, in composition complex therapy of recurrent herpes zoster for HIV-infected patients and patients without an immunodeficit.

Patients and Methods. The quantity of examined and treated patients with recurrent herpes zoster were 56 people, including 16 HIV-positive and 40 patients without immunodeficiency. For a representative sample, patients were divided into four groups. The first main group included 19 immunocompetent patients with herpes zoster, the second primary – 8 HIV-infected patients with herpes zoster. These persons against the background of basic therapy (daily intake of etiotropic medication with international non-proprietary name (INN) valaciclovir – 1.0 g PO BID for 10-14 days, with the transition to the suppressive therapy of 0.5 g BID for 1 month) additionally administered SC injections of 3 immunotropic allokin-alpha, the main active ingredient of which is cytokine-like peptide alloferon, a dose of 1 mg each day. The first and second control group were 21 and 8 patients, respectively, who were administered only specified basic therapy.

Results. It has was found that the only basic therapy by means of daily administration of etiotropic valaciclovir 1.0 g PO 2 BID for 10-14 days in 16 patients with HIV-associated herpes zoster and 40 patients with herpes zoster HIV-negative status does not provide a meaningful clinical effect. The addition by 3 SC injections allokin-alpha given at a dose of 1 mg OD provides a statistically significant reduction in the duration of the clinical manifestations of herpes zoster in patients without immunodeficiency compared with valaciclovir therapy alone (p<0.05). Along with the reduction of recurrence after application of proven drug cytokine-like peptide statistical weight and decreasing the duration of first recurrence of HIVassociated herpes zoster after treatment, it was (7.0±0.6) days. In patients treated only valaciclovir, the rate was (11.3±0.5) day (p<0.05). Appropriate outpatient monitoring of patients in III-IV clinical stage of HIV disease who received only basic therapy of herpes zoster, also did not show any effect on relapse rate (p>0.05). Supplement of the same basic therapy proven drug provided cytokine-like peptide increasing the duration of remission and a significant reduction in recurrence of herpes zoster – of (1.60±0.24) to (0.60±0.24) day for 3 months (p<0.05).

Also, along with a decrease in the frequency of relapses HIV-associated herpes zoster in patients with III-IV clinical stage after applying proven drug cytokinelike peptide weighty and decreasing the duration of the first relapse after treatment – (9.8±0.4) and (16.3±0.6) days, respectively (p<0.05).

Conclusions. Addition of base etiotropic treatment of herpes zoster provides reduction of duration of clinical displays immunotropic preparation allokin-alpha during treatment, reduction of duration of the first relapse after treatment, and also reduction of frequency of relapses both for HIV-infected patients and for patients without an immunodeficit.